Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPreventive Services & ScreeningMutual of Omaha Colorectal Coverage Update | OpenP…
    Ask Trek AI about this page
    ModifiedMutual of OmahaPolicy AHS - G2181

    Colorectal Cancer Screening

    Customize your policy alerts

    Sign up for mutualofomaha Policy AHS - G2181 alerts

    Get alerted when Policy AHS - G2181 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage for colorectal cancer screening tests based on age, symptoms, risk status, test type, and screening interval. It applies to providers requesting coverage, subject to the member’s applicable benefit plan and referenced Medicare or Medicaid provisions.

    Policy Summary
    PayerMutual of Omaha
    PolicyColorectal Cancer Screening
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionCoverage may be denied when screening is requested for an average-risk asymptomatic individual older than 75 years.
    SourceLink
    POLICY UPDATE CHANGES

    CPT code 87626 was added on 03/18/2026.

    CPT code 0537U was revised effective 01/01/2026.

    CPT code 0500T was removed because it was deleted effective 01/01/2025.

    The description for CPT code 87624 was revised effective 01/01/2025.

    The background, guidelines and recommendations, and evidence-based scientific references were updated on 03/18/2026.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    45-75Covered annual FIT or gFOBT age range
    AnnualFIT or gFOBT frequency
    Every 3 yearsFIT-DNA frequency
    75 yearsScreening not covered for average-risk asymptomatic individuals over
    3Explicitly excluded screening techniques
    8Applicable CPT codes listed

    Coverage Criteria

    Annual FIT or gFOBT screening

    Covered when the individual is asymptomatic, 45 to 75 years of age, and receives annual stool-based screening.

    Annual FIT or gFOBT screening: The individual is asymptomatic and 45 to 75 years of age, and colorectal cancer screening is performed annually with a fecal immunochemical test (FIT), preferred, or a guaiac fecal occult blood test (gFOBT).Age 45-75 years; annual

    Meets coverage criteria.

    FIT-DNA screening

    Covered at the stated interval.

    FIT-DNA screening: FIT-DNA, including Cologuard or Cologuard Plus, is used for colorectal cancer screening once every 3 years.Once every 3 years

    The policy states that this meets coverage criteria; the same section also contains a conflicting statement that FIT-DNA does not meet coverage criteria.

    Average-risk adult screening

    Routine screening is recommended for average-risk adults within the applicable age and health criteria.

    Routine screening age groups: Adults aged 45-49 years should be offered screening; adults aged 50-75 years should be screened; adults aged 76-85 years may be screened selectively or after individualized discussion.Age 45-75 years routinely; age 76-85 years individualized

    Consider overall health, life expectancy, comorbidities, prior screening history, CRC risk, and patient preference.

    Screening modality and frequency

    Select an accepted screening modality and follow its recommended interval.

    Accepted screening modalities: Screening may be performed with high-sensitivity FIT, high-sensitivity gFOBT, multitarget stool DNA/FIT-DNA, colonoscopy, CT colonography, flexible sigmoidoscopy, or flexible sigmoidoscopy combined with FIT.FIT or gFOBT annually; multitarget stool DNA every 3 years; colonoscopy every 10 years; CT colonography or flexible sigmoidoscopy every 5 years

    ACG identifies colonoscopy and FIT as primary modalities and suggests alternatives when a patient is unable or unwilling to undergo colonoscopy or FIT.

    Increased familial risk

    Patients with increased familial risk require modified screening.

    Familial risk pathways: For one first-degree relative with CRC or an advanced polyp diagnosed before age 60, or at least two first-degree relatives with CRC or advanced polyps at any age, begin colonoscopy at age 40 or 10 years before the youngest affected relative, whichever is earlier, and repeat every 5 years. For one first-degree relative diagnosed at age 60 or older, begin screening at age 40 or 10 years before the youngest affected relative and then resume average-risk recommendations. One second-degree relative with CRC or an advanced polyp follows average-risk recommendations.Age 40 or 10 years before youngest affected relative; colonoscopy every 5 years for higher familial risk

    Consider genetic evaluation when the familial CRC burden is higher in number or younger age of affected relatives.

    Symptomatic patients

    Symptoms require diagnostic evaluation rather than routine screening.

    Symptomatic evaluation: Patients of any age with symptoms associated with CRC, including rectal bleeding, iron deficiency anemia, diarrhea, abdominal pain, or weight loss, should receive prompt tailored evaluation for gastrointestinal and non-gastrointestinal causes; colonoscopy should be considered in most unexplained cases.Any age with CRC-associated symptoms

    Persistent rectal bleeding initially attributed to hemorrhoids should be considered for colonoscopy if it does not resolve with treatment.

    Cologuard and Cologuard Plus use

    FDA-labeled stool DNA tests are limited to the indicated screening populations.

    FDA-labeled stool DNA testing: Cologuard is indicated for adults aged 50 years or older at typical average risk, and Cologuard Plus is indicated for adults aged 45 years or older at average risk. A positive result should be followed by colonoscopy.Cologuard: age 50 or older; Cologuard Plus: age 45 or older

    Neither test replaces diagnostic or surveillance colonoscopy in high-risk individuals.

    The following screening scenarios do not meet coverage criteria: methylated Septin 9 testing (ColoVantage); colorectal cancer screening with FIT-DNA (Cologuard or Cologuard Plus), as separately stated in the policy; screening of anal cytological abnormalities, including an anal Pap smear; screening for anal HPV infection; and colorectal cancer screening using cell-free DNA techniques, such as Guardant Shield. The policy cites insufficient published scientific literature supporting cell-free DNA techniques for diagnosis and treatment.

    For average-risk, asymptomatic individuals older than 75 years, colorectal cancer screening does not meet coverage criteria. Screening is not recommended after age 85.

    Cologuard and Cologuard Plus are intended for indicated average-risk screening populations and are not indicated for patients with relevant personal or family colorectal cancer risk factors, inflammatory bowel disease, hereditary cancer or polyposis syndromes, or recent positive colorectal screening results. The applicable look-back period for Cologuard Plus includes 12 months for a positive FOBT or FIT and 36 months for a positive FIT-DNA test.

    A positive Cologuard or Cologuard Plus result should be followed by colonoscopy. Neither test is a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

    Coding and Screening Intervals

    Applicable CPT/HCPCS Procedure CodesCPT
    81327SEPT9 (Septin9) (eg, colorectal cancer) promoter methylation analysis.
    81528Oncology (colorectal) screening, quantitative real-time target, and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result.
    82270Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided 3 cards or single triple card for consecutive collection).
    Applicable CPT/HCPCS Procedure CodesCPT
    82274Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations.
    87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types.
    87625Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed.
    87626Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types, separate or pooled result.
    88112Cytopathology, selective cellular enhancement technique with interpretation, except cervical or vaginal.
    Applicable CPT/HCPCS Procedure CodesCPTCovered
    81327SEPT9 (Septin9) (eg, colorectal cancer) promoter methylation analysis.
    81528Oncology (colorectal) screening, quantitative real-time target, and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result
    82270Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided 3 cards or single triple card for consecutive collection)
    82274Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations.
    87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result
    87625Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
    87626Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 45, 51, 52), separate or pooled result
    88112Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid-based slide preparation method), except cervical or vaginal
    Revision History Coding ChangesCPT
    0537URevised effective 01/01/2026.
    0500TRemoved; deleted code effective 01/01/2025.
    Screening intervals
    High-sensitivity gFOBTEvery year
    FITEvery year
    Multitarget stool DNA/FIT-DNAEvery 3 years
    ColonoscopyEvery 10 years
    CT colonographyEvery 5 years
    Flexible sigmoidoscopyEvery 5 years
    Flexible sigmoidoscopy plus FITFlexible sigmoidoscopy every 10 years plus annual FIT

    Provider Actions and Coverage Alerts

    Denial Risk

    Screening Over Age 75

    For average-risk, asymptomatic individuals older than 75 years, colorectal cancer screening does not meet coverage criteria and may be denied.

    Denial Risk

    Excluded Screening Techniques

    The following colorectal cancer screening techniques do not meet coverage criteria because published scientific literature does not confirm that they are required and beneficial for diagnosis and treatment.

    • Anal cytology (anal Pap smear)
    • Anal HPV screening
    • Cell-free DNA colorectal cancer screening, such as Guardant Shield™
    Note

    Benefit-Specific Coverage

    Background

    Colorectal cancer develops in the colon or rectum and is influenced by genetic and environmental risk factors. Screening follows an individual risk assessment and is intended to detect early-stage cancer, adenomatous lesions, and advanced precancerous lesions. Available modalities include stool-based tests and CT colonography; stool-based tests detect fecal hemoglobin or DNA alterations associated with colorectal neoplasia. FIT directly measures hemoglobin in stool and is generally more convenient and more sensitive for colorectal lesions than gFOBT.

    Definitions and Abbreviations

    Definitions
    AAAdvanced adenoma.
    ACAThe Patient Protection and Affordable Care Act.
    ACPMAmerican College of Preventive Medicine.
    ACSAmerican Cancer Society.
    APLAdvanced precancerous lesions.
    CDCCenters for Disease Control and Prevention.
    CLIA '88Clinical Laboratory Improvement Amendments of 1988.
    CMS
    Policy Summary
    PayerMutual of Omaha
    PolicyColorectal Cancer Screening
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionCoverage may be denied when screening is requested for an average-risk asymptomatic individual older than 75 years.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Screening IntervalsProvider Actions and Coverage AlertsBackgroundDefinitions and Abbreviations
    Increased familial risk screening
    Qualifying familial riskColorectal cancer or an advanced polyp in 1 first-degree relative younger than 60 years, or in at least 2 first-degree relatives at any age
    Initiation of colonoscopyAge 40 or 10 years before the youngest affected relative, whichever is earlier
    Repeat intervalEvery 5 years

    Apply coverage criteria according to the member’s benefit coverage at the time of the request. Medicare- and Medicaid-specific provisions may apply; consult the applicable policy section before proceeding.

    • Coverage is benefit-specific.
    • Medicare and Medicaid specifications are addressed in Section VII of the policy.
    Denial Risk

    Cologuard™ Contraindicated Populations

    Before ordering Cologuard™, confirm that the patient is an average-risk screening candidate and does not fall within a contraindicated or unevaluated population. A positive result should be followed by diagnostic colonoscopy.

    • Personal history of colorectal cancer, adenomas, or other related cancers
    • Positive result from another colorectal cancer screening method within the last 6 months
    • High-risk conditions, including inflammatory bowel disease, chronic ulcerative colitis, Crohn’s disease, familial adenomatous polyposis, or a family history of colorectal cancer
    • Relevant familial or hereditary cancer syndromes, including HNPCC/Lynch syndrome, Peutz-Jeghers syndrome, MYH-associated polyposis (MAP), Gardner’s syndrome, Turcot’s/Crail’s syndrome, Cowden’s syndrome, juvenile polyposis, Cronkhite-Canada syndrome, neurofibromatosis, or familial hyperplastic polyposis
    Denial Risk

    Cologuard Plus™ Contraindicated Populations

    Before ordering Cologuard Plus™, confirm that the patient does not have a listed contraindication or high-risk condition. A positive result should be followed by colonoscopy.

    • Personal history of colorectal cancer or advanced precancerous lesions
    • Positive result from another colorectal cancer screening method within the last 6 months; 12 months for a fecal occult blood test (FOBT) or fecal immunochemical test (FIT); or 36 months for a FIT-DNA test
    • Family history of colorectal cancer defined as a first-degree relative (parent, sibling, or child) with colorectal cancer at any age
    • Personal history of inflammatory bowel disease, including chronic ulcerative colitis or Crohn’s disease
    • Relevant familial, hereditary, or other polyposis syndromes, including familial adenomatous polyposis (FAP or Gardner’s), HNPCC/Lynch syndrome, Peutz-Jeghers syndrome, MYH-associated polyposis (MAP), Turcot’s/Crail’s syndrome, Cowden’s syndrome, juvenile polyposis, Cronkhite-Canada syndrome, neurofibromatosis, or serrated polyposis
    Documentation Required

    Screening Tests Are Not Diagnostic or Surveillance Colonoscopy

    Cologuard™ and Cologuard Plus™ are screening tests for average-risk adults, not substitutes for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. A positive result may indicate colorectal cancer or advanced neoplasia and requires appropriate colonoscopic follow-up.

    • Cologuard™ is indicated for average-risk adults aged 50 years or older.
    • Cologuard Plus™ is indicated for average-risk adults aged 45 years or older.
    • Use diagnostic colonoscopy after a positive result.
    • Do not use either product as a replacement for diagnostic or surveillance colonoscopy in high-risk individuals.
    Centers for Medicare and Medicaid Services.
    CRCColorectal cancer.
    CTComputerized tomography.
    CUCChronic ulcerative colitis.
    DNADeoxyribonucleic acid.
    EDTAEthylenediaminetetraacetic acid.
    FAPFamilial adenomatous polyposis.
    FDAFood and Drug Administration.
    FITFecal immunochemical test.
    FIT-DNAFecal immunochemical test plus DNA test (multi-target).
    gFOBTGuaiac fecal occult blood test.
    HNPCCCHereditary non-polyposis colorectal cancer syndrome.
    IBDInflammatory bowel disease.
    IOMInstitute of Medicine.
    KRASKRAS proto-oncogene, GTPase.
    MAPMYH-associated polyposis.
    MDMMethylated DNA markers.
    MSTFU.S. Multi-Society Task Force on Colorectal Cancer.
    mt-sDNAMulti-target stool DNA.
    NRASNRAS proto-oncogene, GTPase.
    PCRPolymerase chain reaction.
    USPSTFU.S. Preventive Services Task Force.
    Asymptomatic screening population
    PopulationPeople being considered for colorectal cancer screening.
    Required symptom statusAsymptomatic for the condition being screened.
    Recommendation scopeUSPSTF recommendations in this document apply to people who are asymptomatic for the condition being screened.
    Laboratory-developed test (LDT)
    DevelopmentDeveloped by a laboratory.
    Validation and performanceValidated and performed in-house by that laboratory.
    Regulatory classificationRegulated by CMS as a high-complexity test under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88).
    FDA statusNot approved or cleared by the U.S. Food and Drug Administration; FDA clearance or approval is not currently required for clinical use.
    Average risk for colorectal cancer
    Personal riskExcludes a personal history of colorectal cancer, adenomas, advanced precancerous lesions, or related cancers.
    Family riskExcludes a family history of colorectal cancer, including a first-degree relative with colorectal cancer.
    Inflammatory bowel disease riskExcludes inflammatory bowel disease, including chronic ulcerative colitis and Crohn's disease.
    Hereditary cancer or polyposis riskExcludes relevant hereditary cancer or polyposis syndromes, including familial adenomatous polyposis and hereditary non-polyposis colorectal cancer syndrome.